Ana Lluch Hernández-rekin lankidetzan egindako argitalpenak (11)

2009

  1. Guidelines for HER2 testing in breast cancer. A national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Revista Espanola de Patologia, Vol. 42, Núm. 1, pp. 3-16

  2. Guidelines for HER2 testing in breast cancer: A national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 11, Núm. 6, pp. 363-375

2007

  1. Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies

    Leukemia, Vol. 21, Núm. 7, pp. 1413-1422

2003

  1. Mobilization of peripheral blood progenitor cells with a combination of cyclophosphamide, r-metHuSCF and filgrastim in patients with breast cancer previously treated with chemotherapy

    Leukemia, Vol. 17, Núm. 2, pp. 437-441

2001

  1. Prognostic significance of the immunocytochemical detection of contaminating tumor cells (CTC) in apheresis products of patients with high-risk breast cancer treated with high-dose chemotherapy and stem cell transplantation

    Bone Marrow Transplantation, Vol. 27, Núm. 3, pp. 287-293

2000

  1. Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome

    Bone Marrow Transplantation, Vol. 25, Núm. 11, pp. 1203-1208

1999

  1. Mobilization of peripheral blood progenitor cells (PBPC) in patients undergoing chemotherapy followed by autologous peripheral blood stem cell transplant (SCT) for high risk breast cancer (HRBC)

    Bone Marrow Transplantation, Vol. 23, Núm. 11, pp. 1101-1107

  2. Prognostic factors in patients with isolated recurrences of breast cancer (stage IV-NED)

    Breast Cancer Research and Treatment, Vol. 53, Núm. 2, pp. 105-112

  3. Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: Analysis of 439 patients

    Breast Cancer Research and Treatment, Vol. 56, Núm. 1, pp. 67-78

1998

  1. CD44 isoforms in breast carcinoma: Clinical implications and prognostic significance

    Experimental Hematology, Vol. 26, Núm. 8, pp. 705

  2. Comparison between mobilization with g-csf versus g-csf plus cyclophosphamide based chemotherapy fn patients with breast cancer

    Experimental Hematology, Vol. 26, Núm. 8, pp. 780